{"filing":{"accession_number":"0001213900-26-100119","cik":"0001833498","ticker":"MDAIW","company_name":"Spectral AI, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-14","primary_document":"ea0305581-8k_spectral.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026100119/ea0305581-8k_spectral.htm"},"events":[{"id":33596,"run_id":30897,"accession_number":"0001213900-26-100119","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses an investor presentation posted on September 14, 2026, under Item 7.01 (Regulation FD Disclosure). The presentation details Spectral AI's FDA De Novo clearance (May 2026), BARDA contract status ($150M total with $31.7M exercised), commercial launch strategy, and financial position. While the FDA clearance itself is a regulatory milestone, the primary disclosure here is the investor presentation itself—a strategic communication about the company's product commercialization, market opportunity, and capital deployment plans. This is an operational/strategic disclosure rather than a specific event type (not earnings, M\u0026A, litigation, etc.), making it operational_other. It is material because it communicates significant regulatory achievements, government funding, commercial milestones, and financial position to investors.","company_name":"Spectral AI, Inc.","ticker":"MDAIW","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":37080,"accession_number":"0001213900-26-100119","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses an investor presentation posted on September 14, 2026, under Item 7.01 (Regulation FD Disclosure). The presentation details Spectral AI's FDA De Novo clearance (May 2026), BARDA contract status ($150M total with $31.7M exercised), commercial launch strategy, and financial position. While the FDA clearance itself is a regulatory milestone, the primary disclosure here is the investor presentation itself—a strategic communication about the company's product commercialization, market opportunity, and capital deployment plans. This is an operational/strategic disclosure rather than a specific event type (not earnings, M\u0026A, litigation, etc.), making it operational_other. It is material because it communicates significant regulatory achievements, government funding, commercial milestones, and financial position to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:04:42.560345+00:00","company_name":"Spectral AI, Inc.","ticker":"MDAIW","filing_date":"2026-09-15"}]}